
Karen E Willard-Gallo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2945554/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	CD4+ follicular helper T cell infiltration predicts breast cancer survival. Journal of Clinical Investigation, 2013, 123, 2873-2892. Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and	3.9	813
2	Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non–Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Cenitourinary Carcinomas, and Primary Brain Tumors, Advances in Anatomic Pathology, 2017, 24, States in Burner Carcinomas, and Primary Brain Tumors, Advances in Anatomic Pathology, 2017, 24,	2.4	530
3	Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. Advances in Anatomic	2.4	469
4	CXCL13-producing TFH cells link immune suppression and adaptive memory in human breast cancer. JCI Insight, 2017, 2, .	2.3	258
5	Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group. Modern Pathology, 2016, 29, 1155-1164.	2.9	230
6	lmmune evasion before tumour invasion in early lung squamous carcinogenesis. Nature, 2019, 571, 570-575.	13.7	227
7	Tumor-infiltrating B cells signal functional humoral immune responses in breast cancer. JCI Insight, 2019, 4, .	2.3	182
8	Principles Governing A-to-I RNA Editing in the Breast Cancer Transcriptome. Cell Reports, 2015, 13, 277-289.	2.9	179
9	Tumor-infiltrating lymphocyte composition, organization and PD-1/ PD-L1 expression are linked in breast cancer. Oncolmmunology, 2017, 6, e1257452.	2.1	169
10	The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group. Npj Breast Cancer, 2021, 7, 150.	2.3	112
11	State-of-the-Art Lentiviral Vectors for Research Use: Risk Assessment and Biosafety Recommendations. Current Gene Therapy, 2009, 9, 459-474.	0.9	109
12	Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. Npj Breast Cancer, 2020, 6, 17.	2.3	106
13	The rationale behind targeting the ICOS-ICOS ligand costimulatory pathway in cancer immunotherapy. ESMO Open, 2020, 5, e000544.	2.0	95
14	Reliability of tumor-infiltrating lymphocyte and tertiary lymphoid structure assessment in human breast cancer. Modern Pathology, 2017, 30, 1204-1212.	2.9	81
15	Immune Checkpoint Molecules on Tumor-Infiltrating Lymphocytes and Their Association with Tertiary Lymphoid Structures in Human Breast Cancer. Frontiers in Immunology, 2017, 8, 1412.	2.2	80
16	Immune Infiltration in Invasive Lobular Breast Cancer. Journal of the National Cancer Institute, 2018, 110, 768-776.	3.0	76
17	Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials. Cancer Treatment Reviews, 2017, 57, 8-15.	3.4	75
18	LAG3: The Biological Processes That Motivate Targeting This Immune Checkpoint Molecule in Human Cancer. Cancers, 2019, 11, 1213.	1.7	75

KAREN E WILLARD-GALLO

#	Article	IF	CITATIONS
19	Functional Th1-oriented T follicular helper cells that infiltrate human breast cancer promote effective adaptive immunity. Journal of Clinical Investigation, 2021, 131, .	3.9	70
20	Antigen Specificity and Clinical Significance of IgG and IgA Autoantibodies Produced in situ by Tumor-Infiltrating B Cells in Breast Cancer. Frontiers in Immunology, 2018, 9, 2660.	2.2	65
21	Immunity drives <i>TET1</i> regulation in cancer through NF-κB. Science Advances, 2018, 4, eaap7309.	4.7	64
22	Tumor-Infiltrating Lymphocytes in Patients Receiving Trastuzumab/Pertuzumab-Based Chemotherapy: A TRYPHAENA Substudy. Journal of the National Cancer Institute, 2019, 111, 69-77.	3.0	60
23	Bortezomib (PS-341, Velcade) increases the efficacy of trastuzumab (Herceptin) in HER-2–positive breast cancer cells in a synergistic manner. Molecular Cancer Therapeutics, 2006, 5, 3042-3051.	1.9	58
24	Critical features and challenges associated with imaging in patients undergoing cancer immunotherapy. Critical Reviews in Oncology/Hematology, 2017, 120, 13-21.	2.0	56
25	Immunotherapy Associated Pulmonary Toxicity: Biology Behind Clinical and Radiological Features. Cancers, 2019, 11, 305.	1.7	51
26	Significance of TIM3 expression in cancer: From biology to the clinic. Seminars in Oncology, 2019, 46, 372-379.	0.8	49
27	Cancer immunotherapy-associated hypophysitis. Seminars in Oncology, 2018, 45, 181-186.	0.8	47
28	Inhibition of RANK signaling in breast cancer induces an anti-tumor immune response orchestrated by CD8+ T cells. Nature Communications, 2020, 11, 6335.	5.8	46
29	Programmed cell death-ligand 2: A neglected but important target in the immune response to cancer?. Translational Oncology, 2020, 13, 100811.	1.7	46
30	6q- is an early and persistent chromosomal aberration in CD3-CD4+ T-cell clones associated with the lymphocytic variant of hypereosinophilic syndrome. Haematologica, 2005, 90, 753-65.	1.7	41
31	Identification of Three NFAT Binding Motifs in the 5′-Upstream Region of the Human CD3γ Gene That Differentially Bind NFATc1, NFATc2, and NF-κB p50. Journal of Biological Chemistry, 2002, 277, 47136-47148.	1.6	39
32	FOXP1 negatively regulates tumor infiltrating lymphocyte migration in human breast cancer. EBioMedicine, 2019, 39, 226-238.	2.7	36
33	FOXP1 is a regulator of quiescence in healthy human CD4 ⁺ T cells and is constitutively repressed in T cells from patients with lymphoproliferative disorders. European Journal of Immunology, 2017, 47, 168-179.	1.6	35
34	Breast cancer vaccines: Heeding the lessons of the past to guide a path forward. Cancer Treatment Reviews, 2020, 84, 101947.	3.4	35
35	Molecular profiling of CD3â^'CD4+ T cells from patients with the lymphocytic variant of hypereosinophilic syndrome reveals targeting of growth control pathways. Blood, 2009, 114, 2969-2983.	0.6	34
36	Tumor-infiltrating follicular helper T cells: The new kids on the block. OncoImmunology, 2013, 2, e26066.	2.1	34

KAREN E WILLARD-GALLO

#	Article	IF	CITATIONS
37	A Simple and Rapid Protocol to Non-enzymatically Dissociate Fresh Human Tissues for the Analysis of Infiltrating Lymphocytes. Journal of Visualized Experiments, 2014, , .	0.2	33
38	BRCA gene mutations do not shape the extent and organization of tumor infiltrating lymphocytes in triple negative breast cancer. Cancer Letters, 2019, 450, 88-97.	3.2	33
39	Luminal Breast Cancer: Risk of Recurrence and Tumor-Associated Immune Suppression. Molecular Diagnosis and Therapy, 2021, 25, 409-424.	1.6	33
40	T follicular helper and B cell crosstalk in tertiary lymphoid structures and cancer immunotherapy. Nature Communications, 2022, 13, 2259.	5.8	32
41	Downregulation of the FTO m6A RNA demethylase promotes EMT-mediated progression of epithelial tumors and sensitivity to Wnt inhibitors. Nature Cancer, 2021, 2, 611-628.	5.7	30
42	PD-1 hi CXCR5 â^' CD4 + T FH Cells Play Defense in Cancer and Offense in Arthritis. Trends in Immunology, 2017, 38, 875-878.	2.9	26
43	The Abscopal Effect in the Era of Cancer Immunotherapy: a Spontaneous Synergism Boosting Anti-tumor Immunity?. Targeted Oncology, 2018, 13, 113-123.	1.7	26
44	Radiomics and "radi-…omics―in cancer immunotherapy: a guide for clinicians. Critical Reviews in Oncology/Hematology, 2020, 154, 103068.	2.0	26
45	Immune Checkpoint Inhibitor-Induced Pancreatic Injury: Imaging Findings and Literature Review. Targeted Oncology, 2020, 15, 25-35.	1.7	25
46	Targeting <scp>CTLA</scp> â€4 in cancer: Is it the ideal companion for <scp>PD</scp> â€1 blockade immunotherapy combinations?. International Journal of Cancer, 2021, 149, 31-41.	2.3	23
47	Defective CD3Î ³ gene transcription is associated with NFATc2 overexpression in the lymphocytic variant of hypereosinophilic syndrome. Experimental Hematology, 2005, 33, 1147-1159.	0.2	21
48	Tumor-Derived Thymic Stromal Lymphopoietin Expands Bone Marrow B-cell Precursors in Circulation to Support Metastasis. Cancer Research, 2019, 79, 5826-5838.	0.4	21
49	Fluorescent Multiplex Immunohistochemistry Coupled With Other State-Of-The-Art Techniques to Systematically Characterize the Tumor Immune Microenvironment. Frontiers in Molecular Biosciences, 2021, 8, 673042.	1.6	19
50	Circulating (CD3 ^{â^'} CD19 ⁺ CD20 ^{â^'} IgD ^{â^'} CD27 ^{high} CD38< Plasmablasts: A Promising Cellular Biomarker for Immune Activity for Anti-PLA2R1 Related Membranous Nephropathy?. Mediators of Inflammation, 2016, 2016, 1-10.	∶sup>high∢ 1.4)
51	The impact of tumor cell metabolism on T cell-mediated immune responses and immuno-metabolic biomarkers in cancer. Seminars in Cancer Biology, 2018, 52, 66-74.	4.3	18
52	Targeting PD-1 in cancer: Biological insights with a focus on breast cancer. Critical Reviews in Oncology/Hematology, 2019, 142, 35-43.	2.0	18
53	RNA Based Approaches to Profile Oncogenic Pathways From Low Quantity Samples to Drive Precision Oncology Strategies. Frontiers in Genetics, 2020, 11, 598118.	1.1	18
54	Radiological evaluation of response to immunotherapy in brain tumors: Where are we now and where are we going?. Critical Reviews in Oncology/Hematology, 2018, 126, 135-144.	2.0	14

#	Article	IF	CITATIONS
55	QUANTITATIVE FLUORESCENCE ANALYSIS OF CYCLOSPORINE BINDING TO HUMAN LEUKOCYTES. Transplantation, 1984, 37, 276-280.	0.5	13
56	Transcriptional Regulation of the Human <i>CD3</i> γ Gene: The TATA-Less <i>CD3</i> γ Promoter Functions via an Initiator and Contiguous Sp-Binding Elements. Journal of Immunology, 2005, 174, 6238-6249.	0.4	13
57	Pertussis toxin activates adult and neonatal naive human CD4+ T lymphocytes. European Journal of Immunology, 2006, 36, 1794-1804.	1.6	13
58	Protein mapping of two metallothionein-rich cell strains and their parent lines, using high-resolution two-dimensional electrophoresis. Analytical Biochemistry, 1984, 143, 170-178.	1.1	11
59	A review of immune checkpoint blockade in breast cancer. Seminars in Oncology, 2021, 48, 208-225.	0.8	11
60	Analysis of Normal Subset-specific and Disease-specific Human Leukocyte Proteins by Cell Sorting and Two-dimensional Electrophoresis. Annals of the New York Academy of Sciences, 1984, 428, 201-222.	1.8	10
61	Tumour-infiltrating lymphocytes in non-invasive breast cancer: A systematic review and meta-analysis. Breast, 2021, 59, 183-192.	0.9	10
62	Modulation of CD3-Î ³ Gene Expression after HIV Type 1 Infection of the WE17/10 T Cell Line Is Progressive and Occurs in Concert with Decreased Production of Viral p24 Antigen. AIDS Research and Human Retroviruses, 1996, 12, 715-725.	0.5	9
63	Progressive loss of CD3 expression after HTLV-I infection results from chromatin remodeling affecting all the CD3 genes and persists despite early viral genes silencing. Virology Journal, 2007, 4, 85.	1.4	9
64	IRF5: a rheostat for tumorâ€infiltrating lymphocyte trafficking in breast cancer?. Immunology and Cell Biology, 2015, 93, 425-426.	1.0	9
65	Age-related changes in the BACH2 and PRDM1 genes in lymphocytes from healthy donors and chronic lymphocytic leukemia patients. BMC Cancer, 2019, 19, 81.	1.1	9
66	Human Immunodeficiency Virus Type 2 Produces a Defect in CD3-Î ³ Gene Transcripts Similar to That Observed for Human Immunodeficiency Virus Type 1. Journal of Virology, 1999, 73, 5207-5213.	1.5	9
67	Inflammatory Stroma of Lymphoepithelioma-like Carcinoma of the Cervix. International Journal of Gynecological Pathology, 2018, 37, 482-487.	0.9	7
68	Characterization of Immunoactive and Immunotolerant CD4+ T Cells in Breast Cancer by Measuring Activity of Signaling Pathways That Determine Immune Cell Function. Cancers, 2022, 14, 490.	1.7	7
69	Quantifying Tertiary Lymphoid Structure-Associated Genes in Formalin-Fixed Paraffin-Embedded Breast Cancer Tissues. Methods in Molecular Biology, 2018, 1845, 139-157.	0.4	6
70	Low-Dose Nivolumab with or without Ipilimumab as Adjuvant Therapy Following the Resection of Melanoma Metastases: A Sequential Dual Cohort Phase II Clinical Trial. Cancers, 2022, 14, 682.	1.7	6
71	The Relationship Between Tumor-Infiltrating Lymphocytes, PD-L1 Expression, Driver Mutations and Clinical Outcome Parameters in Non-Small Cell Lung Cancer Adenocarcinoma in Patients with a Limited to no Smoking History. Pathology and Oncology Research, 2020, 26, 1221-1228.	0.9	5
72	A comparative analysis of alterations in protein expression after activation or human immunodeficiency virus, type 1 infection of human CD4+ T cells. Electrophoresis, 1991, 12, 544-553.	1.3	4

#	Article	IF	CITATIONS
73	P3.02c-087 The Relationship of TILs and PD-L1 Expression in NSCLC Adenocarcinoma in Little to Non-Smokers with Driver Mutations and Outcome Parameters. Journal of Thoracic Oncology, 2017, 12, S1331.	0.5	2
74	A Rare Case of Hepatic Vanishing Bile Duct Syndrome Occurring after Combination Therapy with Nivolumab and Cabozantinib in a Patient with Renal Carcinoma. Diagnostics, 2022, 12, 539.	1.3	2
75	Tumour-Infiltrating Lymphocytes (TILs) in Breast Cancer: a Predictive or a Prognostic Marker?. Current Breast Cancer Reports, 2015, 7, 59-70.	0.5	1
76	Aging and Malignant Hemopathies: A Complex Multistep Process. , 2018, , 1-13.		1
77	Immunology of Solid Tumors Beyond Tumor-Infiltrating Lymphocytes: The Role of Tertiary Lymphoid Structures. , 2017, , 259-280.		0
78	Transcription Factors and Checkpoint Inhibitor Expression with Age: Markers of Immunosenescence?. Blood, 2016, 128, 5983-5983.	0.6	0
79	Demographic and laboratory determinants of humoral immune responses and impact of different anti-SARS-CoV-2 vaccine platforms in patients with cancer: A systematic review and meta-analysis Journal of Clinical Oncology, 2022, 40, 1543-1543.	0.8	0
80	Impact of cancer diagnosis, stage, and systemic therapies on immunogenicity after COVID-19 vaccination in patients with cancer: A systematic review and meta-analysis Journal of Clinical Oncology, 2022, 40, 1537-1537.	0.8	0